Literature DB >> 27701881

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis.

Samuel Raimundo Fernandes1, Patrícia Santos2, Carlos Miguel Moura2, Pedro Marques da Costa2, Joana Rita Carvalho3, Ana Isabel Valente4, Cilénia Baldaia2, Ana Rita Gonçalves5, Paula Moura Santos5, Luís Araújo-Correia5, José Velosa6.   

Abstract

BACKGROUND: Acute severe colitis (ASC) remains a challenging complication of ulcerative colitis. The early identification of patients who will not respond to optimal therapy is warranted. Increasing evidence suggests that endoscopy may play a role in predicting important outcomes in acute severe colitis.
METHODS: The endoscopic activity of consecutive patients with acute severe colitis was evaluated using the Mayo endoscopic sub-score (Mayo) and the ulcerative colitis endoscopic index of severity (UCEIS). Two segmental indexes were also produced by summing the scores of the rectum and sigmoid (seg-Mayo and seg-UCEIS, respectively). Endpoints included the need for salvage therapy with infliximab or cyclosporine, refractoriness to corticosteroids, and colectomy.
RESULTS: Of one hundred and eight patients enrolled in the study, 60 (55.6%) were male; with a median age of 34.5 years (range 15-80). All patients received intravenous steroids. Fifty-nine patients (55.6%) showed an incomplete or absent response to steroids, 35 patients (34.3%) received salvage therapy with infliximab or cyclosporine and 38 patients (33.3%) were colectomized during the index hospitalization or within the first year of follow-up. All scores were able to predict the need for surgery, but only the seg-UCEIS significantly predicted refractoriness to steroids.
CONCLUSIONS: There was a strong correlation between endoscopic severity and unfavorable outcomes. The UCEIS outperformed the Mayo endoscopic sub-score in all important outcomes. Segmental scoring further improved the performance of the UCEIS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27701881     DOI: 10.17235/reed.2016.4470/2016

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  5 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 2.  Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?

Authors:  Ala I Sharara; Maher Malaeb; Matthias Lenfant; Marc Ferrante
Journal:  Inflamm Intest Dis       Date:  2021-08-18

3.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

4.  Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study.

Authors:  Nienke Z Borren; Hamed Khalili; Jay Luther; Francis P Colizzo; John J Garber; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2019-03-14       Impact factor: 5.325

5.  DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.

Authors:  Hagar Taman; Christopher G Fenton; Endre Anderssen; Jon Florholmen; Ruth H Paulssen
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.